Fate Therapeutics Inc. (FATE) Director William H. Rastetter Purchases 375,939 Shares of Stock
Fate Therapeutics Inc. (NASDAQ:FATE) Director William H. Rastetter acquired 375,939 shares of the stock in a transaction dated Wednesday, November 23rd. The shares were bought at an average price of $2.66 per share, with a total value of $999,997.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Fate Therapeutics Inc. (NASDAQ:FATE) opened at 3.09 on Tuesday. The firm has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.28. The firm’s market cap is $105.52 million. Fate Therapeutics Inc. has a 52 week low of $1.46 and a 52 week high of $4.67.
Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. Fate Therapeutics had a negative return on equity of 112.48% and a negative net margin of 740.69%. On average, equities research analysts predict that Fate Therapeutics Inc. will post ($1.14) earnings per share for the current year.
WARNING: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/fate-therapeutics-inc-fate-director-william-h-rastetter-purchases-375939-shares-of-stock.html.
FATE has been the subject of a number of research analyst reports. BMO Capital Markets set a $4.00 target price on Fate Therapeutics and gave the stock a “buy” rating in a report on Monday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, August 9th. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Thursday, August 11th. Roth Capital initiated coverage on Fate Therapeutics in a report on Thursday, September 22nd. They issued a “buy” rating and a $8.00 target price for the company. Finally, Wedbush lowered their target price on Fate Therapeutics from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, November 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Fate Therapeutics currently has a consensus rating of “Buy” and an average price target of $5.79.
Several institutional investors have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of Fate Therapeutics by 51.3% in the third quarter. Northern Trust Corp now owns 38,625 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 13,094 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Fate Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 68,444 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 4,941 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 15,701 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Fate Therapeutics during the second quarter valued at $137,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Fate Therapeutics by 448.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 204,447 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 167,194 shares in the last quarter. Hedge funds and other institutional investors own 57.07% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Stock Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related stocks with our FREE daily email newsletter.